AU2014278231B2 - Urea derivatives and uses thereof - Google Patents

Urea derivatives and uses thereof Download PDF

Info

Publication number
AU2014278231B2
AU2014278231B2 AU2014278231A AU2014278231A AU2014278231B2 AU 2014278231 B2 AU2014278231 B2 AU 2014278231B2 AU 2014278231 A AU2014278231 A AU 2014278231A AU 2014278231 A AU2014278231 A AU 2014278231A AU 2014278231 B2 AU2014278231 B2 AU 2014278231B2
Authority
AU
Australia
Prior art keywords
certain embodiments
substituted
instance
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014278231A
Other languages
English (en)
Other versions
AU2014278231A1 (en
Inventor
Elizabeth ENLOW
John T. FEUTRILL
Jinsoo Kim
Minh N. NGUYEN
Pawel W. NOWAK
Winston Z. ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Bio Inc filed Critical Kala Bio Inc
Publication of AU2014278231A1 publication Critical patent/AU2014278231A1/en
Assigned to KALA PHARMACEUTICALS, INC. reassignment KALA PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: ENLOW, Elizabeth, KALA PHARMACEUTICALS, INC., KIM, JINSOO, NGUYEN, Minh N.
Application granted granted Critical
Publication of AU2014278231B2 publication Critical patent/AU2014278231B2/en
Priority to AU2017219063A priority Critical patent/AU2017219063B2/en
Priority to AU2020233692A priority patent/AU2020233692B2/en
Assigned to KALA BIO, Inc. reassignment KALA BIO, Inc. Request to Amend Deed and Register Assignors: KALA PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2014278231A 2013-06-11 2014-06-11 Urea derivatives and uses thereof Ceased AU2014278231B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017219063A AU2017219063B2 (en) 2013-06-11 2017-08-24 Urea derivatives and uses thereof
AU2020233692A AU2020233692B2 (en) 2013-06-11 2020-09-16 Urea derivatives and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361833853P 2013-06-11 2013-06-11
US61/833,853 2013-06-11
US201361898720P 2013-11-01 2013-11-01
US61/898,720 2013-11-01
PCT/US2014/041930 WO2014201127A2 (en) 2013-06-11 2014-06-11 Urea derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017219063A Division AU2017219063B2 (en) 2013-06-11 2017-08-24 Urea derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2014278231A1 AU2014278231A1 (en) 2015-12-24
AU2014278231B2 true AU2014278231B2 (en) 2017-05-25

Family

ID=52022933

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014278231A Ceased AU2014278231B2 (en) 2013-06-11 2014-06-11 Urea derivatives and uses thereof
AU2017219063A Ceased AU2017219063B2 (en) 2013-06-11 2017-08-24 Urea derivatives and uses thereof
AU2020233692A Expired - Fee Related AU2020233692B2 (en) 2013-06-11 2020-09-16 Urea derivatives and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017219063A Ceased AU2017219063B2 (en) 2013-06-11 2017-08-24 Urea derivatives and uses thereof
AU2020233692A Expired - Fee Related AU2020233692B2 (en) 2013-06-11 2020-09-16 Urea derivatives and uses thereof

Country Status (6)

Country Link
US (9) US9212145B2 (enExample)
EP (1) EP3030239A4 (enExample)
JP (4) JP6469661B2 (enExample)
AU (3) AU2014278231B2 (enExample)
CA (1) CA2914815A1 (enExample)
WO (1) WO2014201127A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014278231B2 (en) 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof
WO2016094710A1 (en) * 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1 -amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
CA3005723A1 (en) * 2015-11-20 2017-05-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
WO2018090976A1 (zh) * 2016-11-17 2018-05-24 思路迪（北京）医药科技有限公司 一种具有抗癌作用的化合物及其制备方法和应用
JP7426754B2 (ja) 2019-12-16 2024-02-02 スーチョウ レイモン ファーマシューティカルズ カンパニー リミテッド ナフチルウレア化合物の使用
PY2089159A (es) * 2019-12-31 2022-05-11 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CN115487183B (zh) * 2021-06-18 2024-07-26 苏州锐明新药研发有限公司 萘脲类化合物在制备治疗翼状胬肉的药物中的应用
AU2022488910A1 (en) * 2022-12-13 2025-06-19 Suzhou Raymon Pharmaceuticals Company, Ltd. Use of naphthylurea compounds in preparation of drugs for treating pterygium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003141A1 (en) * 2010-07-02 2012-01-05 Alcon Research, Ltd. Compounds for the treatment of posterior segment disorders and diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
JPH0959276A (ja) * 1995-08-11 1997-03-04 Kumiai Chem Ind Co Ltd 縮合ヘテロ環誘導体及び除草剤
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
JP2006500365A (ja) 2002-08-14 2006-01-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
KR100976076B1 (ko) * 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
CN101239978A (zh) * 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
AU2010306671B2 (en) * 2009-10-16 2015-12-17 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
AU2014278231B2 (en) 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003141A1 (en) * 2010-07-02 2012-01-05 Alcon Research, Ltd. Compounds for the treatment of posterior segment disorders and diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, 2007, Vol. 50, No. 7, pages 1584-1597. *

Also Published As

Publication number Publication date
AU2020233692A1 (en) 2020-10-08
AU2017219063B2 (en) 2020-01-30
US10059692B2 (en) 2018-08-28
US20180037572A1 (en) 2018-02-08
US20200299272A1 (en) 2020-09-24
US9212145B2 (en) 2015-12-15
US20160060264A1 (en) 2016-03-03
US9802922B2 (en) 2017-10-31
JP2020143129A (ja) 2020-09-10
JP2022092625A (ja) 2022-06-22
JP6469661B2 (ja) 2019-02-13
JP2016534030A (ja) 2016-11-04
US20180327390A1 (en) 2018-11-15
US20180327389A1 (en) 2018-11-15
US10723719B2 (en) 2020-07-28
AU2020233692B2 (en) 2022-11-24
US10316022B2 (en) 2019-06-11
WO2014201127A3 (en) 2015-02-05
US11352343B2 (en) 2022-06-07
EP3030239A2 (en) 2016-06-15
US20170129876A1 (en) 2017-05-11
US20180037573A1 (en) 2018-02-08
AU2017219063A1 (en) 2017-09-14
EP3030239A4 (en) 2017-03-08
US10059693B2 (en) 2018-08-28
US10329280B2 (en) 2019-06-25
JP7058885B2 (ja) 2022-04-25
US9580421B2 (en) 2017-02-28
JP2019070027A (ja) 2019-05-09
CA2914815A1 (en) 2014-12-18
US20150072986A1 (en) 2015-03-12
AU2014278231A1 (en) 2015-12-24
WO2014201127A2 (en) 2014-12-18
US20190284172A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
AU2020233692B2 (en) Urea derivatives and uses thereof
US20210380588A1 (en) Novel Compounds and Uses Thereof
AU2015360438C1 (en) 1 -amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: KALA BIO, INC.

Free format text: FORMER NAME(S): KALA PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired